2025
Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023
Hurley L, Kurlandsky K, Breslin K, Stein A, Hambidge S, Shoup J, Reifler L, Daley M, Lewin B, Goddard K, Henninger M, Nelson J, Vazquez-Benitez G, Hanson K, Fuller C, Williams J. Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023. Human Vaccines & Immunotherapeutics 2025, 21: 2467548. PMID: 40179339, PMCID: PMC11980469, DOI: 10.1080/21645515.2025.2467548.Peer-Reviewed Original Research
2024
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-Hospital OutcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospital
2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito D, Martin D, Rosen A, Van de Velde N, Vermund S, Gravenstein S, Mansi J. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines 2023, 11: 1711. PMID: 38006043, PMCID: PMC10675676, DOI: 10.3390/vaccines11111711.Peer-Reviewed Original ResearchCOVID-19-related hospitalizationRelative vaccine effectivenessOutpatient visitsPrimary care electronic health recordsCOVID-19-related outcomesVaccine-induced protectionMedical claims dataCOVID-19 vaccineSARS-CoV-2Electronic health recordsVaccine effectivenessVaccine recipientsMRNA vaccinesBivalent vaccineBaseline differencesStudy populationClaims dataOmicron variantComparative effectivenessHospitalizationPropensity scoreVaccineOlder adultsHealth recordsVisitsCharacterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Zendt M, Carrillo F, Kelly S, Saturday T, DeGrange M, Ginigeme A, Wu L, Callier V, Ortega-Villa A, Faust M, Chang-Rabley E, Bugal K, Kenney H, Khil P, Youn J, Osei G, Regmi P, Anderson V, Bosticardo M, Daub J, DiMaggio T, Kreuzburg S, Pala F, Pfister J, Treat J, Ulrick J, Karkanitsa M, Kalish H, Kuhns D, Priel D, Fink D, Tsang J, Sparks R, Uzel G, Waldman M, Zerbe C, Delmonte O, Bergerson J, Das S, Freeman A, Lionakis M, Sadtler K, van Doremalen N, Munster V, Notarangelo L, Holland S, Ricotta E. Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies. Science Advances 2023, 9: eadh3150. PMID: 37824621, PMCID: PMC10569702, DOI: 10.1126/sciadv.adh3150.Peer-Reviewed Original ResearchConceptsHealthy volunteersIgG levelsDose of coronavirus diseaseImmune response to COVID-19 vaccinationResponse to COVID-19 vaccinationAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 infectionMessenger RNA-based vaccinesMedian IgG levelsOrgan transplant populationCoronavirus 2 infectionRNA-based vaccinesImmunomodulating treatmentTransplant populationDose 2Dose 3Prospective cohortCoronavirus diseaseDoseCOVID-19 vaccineOmicron BABivalent vaccineImmunoglobulin GVaccineIgGCOVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023
Taylor C, Patel K, Patton M, Reingold A, Kawasaki B, Meek J, Openo K, Ryan P, Falkowski A, Bye E, Plymesser K, Spina N, Tesini B, Moran N, Sutton M, Talbot H, George A, Havers F, Team C, Team C, Kirley P, Armistead I, Yousey-Hindes K, Oosmanally N, Monroe M, Henderson J, D’Heilly P, Hancock E, Barney G, Bushey S, Billing L, Abdullah N, Schaffner W, Mendez E. COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥65 Years — COVID-NET, 13 States, January–August 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1089-1094. PMID: 37796744, PMCID: PMC10564325, DOI: 10.15585/mmwr.mm7240a3.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationCOVID-19-Associated Hospitalization Surveillance NetworkCOVID-19-associated hospitalization ratesHospitalization ratesAge groupsIntensive care unit admissionMultiple underlying conditionsSevere COVID-19 diseasePromote early treatmentPositive SARS-CoV-2 testSARS-CoV-2 infectionPrevent SARS-CoV-2 infectionYounger age groupsClinical characteristicsUnit admissionUnderlying conditionEarly treatmentSARS-CoV-2 testingIncreased riskSevere COVID-19-associated outcomesSevere outcomesCOVID-19 hospitalizationElevated riskCOVID-19 diseaseBivalent vaccineModelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City
Pandey A, Fitzpatrick M, Moghadas S, Vilches T, Ko C, Vasan A, Galvani A. Modelling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City. The Lancet Regional Health - Americas 2023, 24: 100555. PMID: 37554154, PMCID: PMC10405058, DOI: 10.1016/j.lana.2023.100555.Peer-Reviewed Original ResearchHealthcare costsVaccine dosesInfluenza vaccine coverageCOVID-19 illnessDirect healthcare costsSevere health outcomesCOVID-19 vaccineCOVID-19 burdenNew York CityBooster vaccineVaccine coverageVaccination ratesBivalent vaccineBase case scenarioHealth outcomesEligible residentsProbable casesDisease controlVaccineCanadian InstituteCOVID-19VaccinationHealth researchCommonwealth FundOutcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply